# A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

> **NCT05603195** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 80 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** REGN7508 (IV)
- **DRUG:** REGN7508 (SC)
- **DRUG:** Matching Placebo (IV)
- **DRUG:** Matching Placebo (SC)

## Key facts

- **NCT ID:** NCT05603195
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-12
- **Primary completion:** 2024-09-17
- **Final completion:** 2024-09-17
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05603195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05603195, "A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05603195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*